BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Reshma Mahtani; Bryan Schneider; Guanglong Jiang; Tarah J. Ballinger; Fei Shen; Christopher Chitambar; Rita Nanda; Carla Falkson; Filipa C. Lynce; Christopher Gallagher; Claudine Isaacs; Marcelo Blaya; Elisavet Paplomata; Radhika Walling; Karen Daily; Michael Thompson; Robert Graham; Maureen E. Cooper; Dean C. Pavlick; Jeffrey Gregg; Jeffrey P. Solzak; Yu-Hsiang Chen; Casey L. Bales; Erica Cantor; Bradley A. Hancock; Nawal Kassem; Paul R. Helft; Bert H. O'Neil; Anna Maria V. Storniolo; Sunil Badve; Kathy Miller; Milan Radovich

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Reshma Mahtani, Bryan Schneider, Guanglong Jiang, Tarah J. Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C. Lynce, Christopher Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Michael Thompson, Robert Graham, Maureen E. Cooper, Dean C. Pavlick, Jeffrey GreggJeffrey P. Solzak, Yu-Hsiang Chen, Casey L. Bales, Erica Cantor, Bradley A. Hancock, Nawal Kassem, Paul R. Helft, Bert H. O'Neil, Anna Maria V. Storniolo, Sunil Badve, Kathy Miller, Milan Radovich

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	40
State	Published - 2021

Disciplines

Medicine and Health Sciences

Cite this

Mahtani, R., Schneider, B., Jiang, G., Ballinger, T. J., Shen, F., Chitambar, C., Nanda, R., Falkson, C., Lynce, F. C., Gallagher, C., Isaacs, C., Blaya, M., Paplomata, E., Walling, R., Daily, K., Thompson, M., Graham, R., Cooper, M. E., Pavlick, D. C., ... Radovich, M. (2021). BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology, 40.

Mahtani, R, Schneider, B, Jiang, G, Ballinger, TJ, Shen, F, Chitambar, C, Nanda, R, Falkson, C, Lynce, FC, Gallagher, C, Isaacs, C, Blaya, M, Paplomata, E, Walling, R, Daily, K, Thompson, M, Graham, R, Cooper, ME, Pavlick, DC, Gregg, J, Solzak, JP, Chen, Y-H, Bales, CL, Cantor, E, Hancock, BA, Kassem, N, Helft, PR, O'Neil, BH, Storniolo, AMV, Badve, S, Miller, K & Radovich, M 2021, 'BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer', Journal of Clinical Oncology, vol. 40.

@article{e59f7fbbb6a24265bd533bc9a58a8b36,

title = "BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer",

author = "Reshma Mahtani and Bryan Schneider and Guanglong Jiang and Ballinger, \{Tarah J.\} and Fei Shen and Christopher Chitambar and Rita Nanda and Carla Falkson and Lynce, \{Filipa C.\} and Christopher Gallagher and Claudine Isaacs and Marcelo Blaya and Elisavet Paplomata and Radhika Walling and Karen Daily and Michael Thompson and Robert Graham and Cooper, \{Maureen E.\} and Pavlick, \{Dean C.\} and Jeffrey Gregg and Solzak, \{Jeffrey P.\} and Yu-Hsiang Chen and Bales, \{Casey L.\} and Erica Cantor and Hancock, \{Bradley A.\} and Nawal Kassem and Helft, \{Paul R.\} and O'Neil, \{Bert H.\} and Storniolo, \{Anna Maria V.\} and Sunil Badve and Kathy Miller and Milan Radovich",

note = "Genomically directed therapy was not superior to TPC for patients with residual TNBC after NAC. Capecitabine should remain the standard of care; however, the activity of other agents in this setting provides rationale for testing optimal combinations to improve outcomes. Circulating tumor DNA should ...",

year = "2021",

language = "American English",

volume = "40",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

AU - Mahtani, Reshma

AU - Schneider, Bryan

AU - Jiang, Guanglong

AU - Ballinger, Tarah J.

AU - Shen, Fei

AU - Chitambar, Christopher

AU - Nanda, Rita

AU - Falkson, Carla

AU - Lynce, Filipa C.

AU - Gallagher, Christopher

AU - Isaacs, Claudine

AU - Blaya, Marcelo

AU - Paplomata, Elisavet

AU - Walling, Radhika

AU - Daily, Karen

AU - Thompson, Michael

AU - Graham, Robert

AU - Cooper, Maureen E.

AU - Pavlick, Dean C.

AU - Gregg, Jeffrey

AU - Solzak, Jeffrey P.

AU - Chen, Yu-Hsiang

AU - Bales, Casey L.

AU - Cantor, Erica

AU - Hancock, Bradley A.

AU - Kassem, Nawal

AU - Helft, Paul R.

AU - O'Neil, Bert H.

AU - Storniolo, Anna Maria V.

AU - Badve, Sunil

AU - Miller, Kathy

AU - Radovich, Milan

N1 - Genomically directed therapy was not superior to TPC for patients with residual TNBC after NAC. Capecitabine should remain the standard of care; however, the activity of other agents in this setting provides rationale for testing optimal combinations to improve outcomes. Circulating tumor DNA should ...

PY - 2021

Y1 - 2021

UR - https://pubmed.ncbi.nlm.nih.gov/34910554/

M3 - Article

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Disciplines

Other files and links

Cite this